{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:37:10Z","timestamp":1707525430747},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,4]]},"DOI":"10.7759\/cureus.48261","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T13:41:06Z","timestamp":1699105266000},"source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Safety of Systemic Ozone Therapy in a Patient With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS)"],"prefix":"10.7759","author":[{"given":"Daniele","family":"Romanello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rotunno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"MELAS syndrome","volume":"163","author":"Koga SJ","year":"1995","unstructured":"Koga SJ, Hodges M, Markin C, Gorman P. MELAS syndrome. West J Med. 1995, 163:379-81.","journal-title":"West J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X20150154","article-title":"When should MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) be the diagnosis?","volume":"73","author":"Lorenzoni PJ","year":"2015","unstructured":"Lorenzoni PJ, Werneck LC, Kay CS, Silvado CE, Scola RH. When should MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) be the diagnosis?. Arq Neuropsiquiatr. 2015, 73:959-67. 10.1590\/0004-282X20150154","journal-title":"Arq Neuropsiquiatr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823a0c7f","article-title":"Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype","volume":"77","author":"Kaufmann P","year":"2011","unstructured":"Kaufmann P, Engelstad K, Wei Y, et al.. Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. 2011, 77:1965-71. 10.1212\/WNL.0b013e31823a0c7f","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216136.61640.79","article-title":"A 3-year clinical follow-up of adult patients with 3243AG in mitochondrial DNA","volume":"66","author":"Majamaa-Voltti KA","year":"2006","unstructured":"Majamaa-Voltti KA, Winqvist S, Remes AM, et al.. A 3-year clinical follow-up of adult patients with 3243AG in mitochondrial DNA. Neurology. 2006, 66:1470-5. 10.1212\/01.wnl.0000216136.61640.79","journal-title":"Neurology"},{"key":"ref5","article-title":"MELAS","author":"El-Hattab AW","year":"2001","unstructured":"El-Hattab AW, Almannai M, Scaglia F, et al.. MELAS. GeneReviews [Internet]. University of Washington, Seattle, WA; 2001."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2326409817697399","article-title":"Arginine and citrulline for the treatment of MELAS syndrome","volume":"5","author":"El-Hattab AW","year":"2017","unstructured":"El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome. J Inborn Errors Metab Screen. 2017, 5:10.1177\/2326409817697399","journal-title":"J Inborn Errors Metab Screen"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.06.004","article-title":"MELAS syndrome: clinical manifestations, pathogenesis, and treatment options","volume":"116","author":"El-Hattab AW","year":"2015","unstructured":"El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015, 116:4-12. 10.1016\/j.ymgme.2015.06.004","journal-title":"Mol Genet Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030634","article-title":"The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases","volume":"20","author":"Di Mauro R","year":"2019","unstructured":"Di Mauro R, Cantarella G, Bernardini R, et al.. The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Int J Mol Sci. 2019, 20:10.3390\/ijms20030634","journal-title":"Int J Mol Sci"},{"key":"ref9","article-title":"Clinical features of MELAS and its relation with A3243G gene point mutation","volume":"8","author":"Zhang J","year":"2015","unstructured":"Zhang J, Guo J, Fang W, Jun Q, Shi K. Clinical features of MELAS and its relation with A3243G gene point mutation. Int J Clin Exp Pathol. 2015, 8:13411-5.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref10","article-title":"Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS)","volume":"49","author":"Kobayashi Y","year":"1991","unstructured":"Kobayashi Y, Momoi MY, Tominaga K, et al.. Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am J Hum Genet. 1991, 49:590-9.","journal-title":"Am J Hum Genet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108465","article-title":"The biological and molecular action of ozone and its derivatives: state-of-the-art, enhanced scenarios, and quality insights","volume":"24","author":"Travagli V","year":"2023","unstructured":"Travagli V, Iorio EL. The biological and molecular action of ozone and its derivatives: state-of-the-art, enhanced scenarios, and quality insights. Int J Mol Sci. 2023, 24:10.3390\/ijms24108465","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/198722-long-term-safety-of-systemic-ozone-therapy-in-a-patient-with-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-melas","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:47Z","timestamp":1707509387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/198722-long-term-safety-of-systemic-ozone-therapy-in-a-patient-with-mitochondrial-encephalomyopathy-lactic-acidosis-and-stroke-like-episodes-melas"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.48261","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,4]]}}}